ABVC Biopharma is focused on the development of innovative therapeutics, particularly in the fields of ophthalmology, psychiatric disorders, and oncology. Their product pipeline includes advanced treatments such as Vitargus® (ABV-1701), a biodegradable vitreous replacement, and several drug candidates targeting major depressive disorder (ABV-1504), ADHD (ABV-1505), and various cancers, including triple-negative breast cancer (ABV-1501) and pancreatic cancer (ABV-1703). The company emphasizes the use of plant-based medicines, leveraging their historical efficacy and reduced side effects, to create a portfolio of natural pharmaceuticals aimed at addressing severe illnesses.

ABVC Biopharma collaborates with prestigious research institutions globally, which supports their commitment to advancing their drug candidates through clinical trials. Their strategic partnerships and ongoing research efforts are designed to bring multiple drugs to commercialization within the next five years. The company’s focus on botanical products aligns with the growing market for herbal medicine, projected to expand significantly in the coming years, highlighting ABVC's dedication to developing safe and effective treatments that can positively impact patient lives.

United States

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company that develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is focused on developing therapies for a range of conditions.

ABVC Biopharma

Company Details